Allen & Overy (A&O) has advised pharma giant Novartis on its $28bn (£17.4bn) acquisition of a majority stake in Alcon, the world’s largest eye-care company, reports The Am Law Daily.
The deal is the second stage of a larger transaction originally struck in spring 2008, when Novartis purchased a 25% stake in Alcon for $10.4bn (£6.5bn), handing the company an option to purchase the 52% of the company owned by Nestle.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
